US20090203623A1 - METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST - Google Patents

METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST Download PDF

Info

Publication number
US20090203623A1
US20090203623A1 US12/368,935 US36893509A US2009203623A1 US 20090203623 A1 US20090203623 A1 US 20090203623A1 US 36893509 A US36893509 A US 36893509A US 2009203623 A1 US2009203623 A1 US 2009203623A1
Authority
US
United States
Prior art keywords
subject
degarelix
treatment
disorder
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/368,935
Other languages
English (en)
Inventor
Tine Kold OLESEN
Bo-Eric Persson
Per CANTOR
Egbert A. van der MEULEN
Jens-Kristian Slott JENSEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring International Center SA
Ferring BV
Original Assignee
Ferring International Center SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20090203623(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring International Center SA filed Critical Ferring International Center SA
Priority to US12/368,935 priority Critical patent/US20090203623A1/en
Publication of US20090203623A1 publication Critical patent/US20090203623A1/en
Priority to US13/458,330 priority patent/US9415085B2/en
Priority to US14/139,922 priority patent/US9579359B2/en
Assigned to FERRING B.V. reassignment FERRING B.V. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VAN DER MEULEN, EGBERT A., OLESEN, TINE KOLD, PERSSON, BO-ERIC, CANTOR, PER, JENSEN, JENS-KRISTIAN SLOTT
Priority to US15/405,552 priority patent/US10729739B2/en
Priority to US16/851,179 priority patent/US10973870B2/en
Priority to US17/199,733 priority patent/US20220031801A1/en
Priority to US17/710,889 priority patent/US20220218782A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • Prostate cancer is a leading cause of morbidity and mortality for men in the industrialized world.
  • the American Cancer Society estimates that during 2007 about 218,890 new cases of prostate cancer will have been diagnosed in the United States alone.
  • Prostate cancer is the second leading cause of cancer death in American men, behind only lung cancer. However, while about 1 man in 6 will be diagnosed with prostate cancer during his lifetime, only 1 man in 35 will actually die of it.
  • the American Cancer Society estimates that 27,050 men in the United States will die of prostate cancer in 2007. Prostate cancer accounts for about 9% of cancer-related deaths in men.
  • PSA prostate-specific antigen
  • prostate cancers are dependent on testosterone for growth, and the current medical management of advanced prostate cancer involves androgen deprivation, which may be achieved by bilateral orchiectomy or by administration of gonadotrophin releasing hormone (GnRH) receptor agonists.
  • GnRH gonadotrophin releasing hormone
  • Removal of the testes (castration) was for many years the standard method of preventing the secretion of male hormones by the gonads as a means for reducing growth of prostate cancers. More recently, secretion of male hormones has been perturbed by chemical means by interfering with production of luteinizing hormone (LH), which regulates the synthesis of the androgens.
  • LH luteinizing hormone
  • GnRH Gonadotrophin releasing hormone
  • GnRH-R Gonadotrophin releasing hormone
  • GnRH-R GnRH receptor
  • leuprolide and goserelin agonists of the GnRH receptor
  • GnRH agonists are generally analogs of GnRH, the decapeptide pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH 2 .
  • GnRH agonists having a D-isomer instead of Gly in the 6-position have greater binding affinity/strength to the receptor and greater biological potency than the native hormone; one example is the [D-Ala 6 ]-GnRH (described in U.S. Pat. No. 4,072,668) having the following formula: pGlu-His-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH 2 .
  • Such GnRH-R agonists initially act to stimulate LH release and only after prolonged treatment act to desensitize GnRH-R such that LH is no longer produced.
  • the initial stimulation of LH production by the agonist leads to an initial surge in the production of male sex hormones such that the initial response to agonist therapy is aggravation, rather than amelioration, of the patient's condition (e.g., tumor growth may increase).
  • This phenomenon known as the “testosterone surge” or “flare reaction,” can last for as long as two to four weeks.
  • each successive administration of the agonist can cause an additional small LH surge (known as the “acute-on chronic” phenomenon) that can further worsen the condition.
  • the testosterone surge stimulates prostate cancer and can lead to a worsening of current symptoms or appearance of new symptoms such as spinal cord compression, bone pain and urethral obstruction (Thompson et al. (1990) J. Urol.
  • GnRH-R gonadotrophin releasing hormone receptor
  • Antagonists of the gonadotrophin releasing hormone receptor have been developed to overcome the “testosterone surge” or “flare reaction” associated with GnRH agonists.
  • GnRH antagonist peptides are frequently associated with the occurrence of histamine-releasing activity. This histamine-releasing activity represents a serious obstacle to the clinical use of such antagonists because histamine release results in adverse side effects such as edema and itching.
  • Such cyanoguanidino moieties are built upon the omega-amino group in an amino acid side chain, such as lysine, ornithine, 4-amino phenylalanine (4Aph) or an extended chain version thereof, such as 4-amino homophenylalanine (4Ahp).
  • GnRH antagonists having such significantly modified or unnatural amino acids in the 5- and 6-positions exhibit good biological potency, and those built upon Aph are generally considered to be particularly potent.
  • Azaline B i.e.
  • GnRH antagonistic decapeptides In addition, to facilitate administration of these compounds to mammals, particularly humans, without significant gelling, it is considered extremely advantageous for such GnRH antagonistic decapeptides to have high solubility in water at normal physiologic pH, i.e. about pH 5 to about pH 7.4.
  • Applicants have found that a relatively low dose of degarelix GnRH antagonist, delivered about once every 28 days (e.g., monthly), can safely and rapidly suppress testosterone levels to therapeutic levels in prostate cancer patients, without causing a testosterone spike and with an appreciably diminished risk of causing an undesirable side effect associated with androgen deprivation therapy such as a cardiac disorder, arthralgia, and/or a urinary tract infection.
  • the invention provides a method of treating prostate cancer in a subject with a reduced likelihood of causing a testosterone spike or other side effect of a gonadotrophin releasing hormone (GnRH) agonist therapy.
  • the method includes administering an initial dose of about 240 mg of degarelix to the subject; and administering a maintenance dose of about 80 mg of degarelix to the subject once every approximately 28 days thereafter, and thereby treating prostate cancer in the subject with a reduced likelihood of causing a testosterone spike or other GnRH agonist side effect.
  • GnRH gonadotrophin releasing hormone
  • the invention provides a method of treating prostate cancer in a subject with a reduced likelihood of causing a testosterone spike or other side effect of a gonadotrophin releasing hormone (GnRH) agonist therapy.
  • the method includes administering an initial dose of 160-320 mg of degarelix to the subject; and administering a maintenance dose of 60-160 mg of degarelix to the subject once every 20-36 days thereafter, and thereby treating prostate cancer in the subject with a reduced likelihood of causing a testosterone spike or other GnRH agonist side effect.
  • GnRH gonadotrophin releasing hormone
  • the maintenance dose is administered monthly.
  • the treated subject has a decreased likelihood of developing or experiencing an undesirable side effect during treatment compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide.
  • the treated subject has a decreased likelihood of developing or experiencing a cardiovascular side effect such as a myocardial infarction, chest pain, a cardiac murmur or a vascular side effect (e.g., deep vein thrombosis (DVT)) during treatment compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide.
  • a cardiovascular side effect such as a myocardial infarction, chest pain, a cardiac murmur or a vascular side effect (e.g., deep vein thrombosis (DVT)
  • the methods provide the treated subject with a decreased likelihood of developing a side effect selected from the group consisting of a cardiac arrhythmia, a coronary artery disorder, and a cardiac disorder.
  • the treated subject has a body mass index (BMI) of less than 30 kg/m 2 , particularly a BMI of less than 25 kg/m 2 .
  • the treated subject has a cholesterol level of greater than or equal to 4 mmol/L (155 mg/dL).
  • the methods of the invention are used to treat a subject who is at risk for cardiovascular disease.
  • the methods of the invention further include the step of identifying a prostate cancer subject who is also at risk for cardiovascular disease for treatment by the method.
  • the treated subject has a decreased likelihood of developing or experiencing an increase in arthralgia and/or musculoskeletal stiffness during treatment compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide.
  • the treated subject has locally advanced prostate cancer and/or is less than 65 years old.
  • the treated subject has a decreased likelihood of developing a musculoskeletal disorder and/or a connective tissue disorder during treatment compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide.
  • GnRH gonadotrophin releasing hormone
  • the musculoskeletal disorder and/or a connective tissue disorder is arthralgia. In other embodiments, the musculoskeletal disorder and/or a connective tissue disorder is musculoskeletal stiffness.
  • the treated subject has a decreased likelihood of developing noninfective cystitis during treatment compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide.
  • GnRH gonadotrophin releasing hormone
  • the treated subject has a decreased likelihood of developing a urinary or renal system disorder compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide.
  • the urinary or renal system disorder is a urinary tract infection.
  • the treated subject has locally advanced prostate cancer.
  • the urinary or renal system disorder is an increase in urinary retention.
  • the urinary or renal system disorder is a noninfective cystitis.
  • the treated subject has a decreased likelihood of developing erectile dysfunction during treatment compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide. In other embodiments, the treated subject has a decreased likelihood of decreased libido during treatment compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide.
  • GnRH gonadotrophin releasing hormone
  • the treated subject has at least about a 95% likelihood of maintaining a therapeutically low serum testosterone level of less than or equal to 0.5 ng/mL by day 28 of treatment. In certain embodiments, the treated subject has at least about a 95% likelihood of maintaining a therapeutically low serum testosterone level of less than or equal to 0.5 ng/mL from day 28 through day 364 of treatment. In still further embodiments, the treated subject has at least about a 30% decrease in prostate specific antigen (PSA) by day 14 of treatment. In particular embodiments, the treated subject has at least about a 50% decrease in prostate specific antigen (PSA) by day 14 of treatment.
  • PSA prostate specific antigen
  • the treated subject has at least about a 60% decrease in prostate specific antigen (PSA) by day 28 of treatment. In still further embodiments, the treated subject has at least about a 75% decrease in prostate specific antigen (PSA) by day 28 of treatment.
  • PSA prostate specific antigen
  • the treated subject has at least about an 80% (e.g., a 95%) likelihood of maintaining a low prostate specific antigen (PSA) level of less than about 5 ng/mL during treatment.
  • PSA prostate specific antigen
  • the treated subject has locally advanced prostate cancer and has at least about a 40% decrease in PSA by day 14 of treatment.
  • the treated subject has metastatic prostate cancer and has at least about a 60% decrease in PSA by day 14 of treatment.
  • the treated subject has a body mass index of less than 30 kg/m 2 (especially less than 25 kg/m 2 ).
  • the invention provides methods of treating prostate cancer in a subject at risk for a cardiovascular disease or disorder by administering a therapeutically effective dose of degarelix to the subject with prostate cancer who is at risk for a cardiovascular disease or disorder.
  • the therapeutically effective dose includes an initial starting dose of 160 to 320 mg of degarelix, and a monthly maintenance dose of 60 to 160 mg of degarelix.
  • the therapeutically effective dose of degarelix includes a maintenance dose of about 80 mg of degarelix once every approximately 28 days of treatment.
  • the therapeutically effective dose of degarelix further includes a single initial dose of about 240 mg of degarelix at the start of treatment.
  • the subject treated has been identified to be at risk of a specific cardiovascular disease or disorder such as cardiac murmur, atrioventricular blockage, and/or myocardial ischemia.
  • the treated subject possesses an indicator of increased risk for cardiovascular disease, e.g. high blood pressure, high low-density lipoprotein cholesterol, low high-density lipoprotein cholesterol, high serum glucose and/or a habitual smoking habit.
  • the treated subject has high blood pressure of greater than or equal to 130 over 85 mm Hg.
  • the treated subject smokes cigarettes daily.
  • the treated subject has an elevated level of low-density lipoprotein cholesterol of greater than or equal to about 160 mg/dl.
  • the treated subject has a low level of high-density lipoprotein cholesterol of less than 35 mg/dl.
  • the treated subject has an elevated fasting glucose level of greater than about 120 mg/dL.
  • the treated subject possesses an indicator of increased risk for cardiovascular disease such as high serum C-reactive protein (CRP), high serum homocysteine, high serum fibrinogen, and/or high serum lipoprotein(a) (Lp(a)).
  • CRP C-reactive protein
  • Lp(a) high serum lipoprotein(a)
  • the treated subject has an elevated level of C-reactive protein of greater than 3 mg/dL.
  • the treated subject has an elevated level of serum homocysteine of greater than 30 ⁇ mol/L.
  • the treated subject has an elevated level of serum fibrinogen of greater than 7.0 g/L.
  • the treated subject has an elevated level of serum Lp(a) of greater than 30 mg/dL.
  • the treated subject has a body mass index of less than 30 kg/m 2 (particularly less than 25 kg/m 2 ).
  • the treated subject has a decreased likelihood, compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide, of developing a cardiovascular side effect such as cardiac arrhythmia, coronary artery disorder, and/or a cardiac disorder.
  • the treated subject has a body mass index (BMI) of less than 30 kg/m 2 (especially less than 25 kg/m 2 ).
  • BMI body mass index
  • the treated subject has a cholesterol level of greater than or equal to 4 mmol/L (155 mg/dL).
  • the invention provides a method of treating prostate cancer in a subject at risk for a cardiovascular disease or disorder by first identifying a suitable subject with prostate cancer that is also at risk for a cardiovascular disease or disorder.
  • the suitable subject with cardiovascular disease risk is then administered an initial dose of about 240 mg of degarelix, followed by a maintenance dose of about 80 mg of degarelix once every approximately 28 days thereafter, thereby treating prostate cancer in the subject at risk for a cardiovascular disease or disorder.
  • the maintenance dose of degarelix is administered monthly.
  • the invention provides a method of treating prostate cancer in a subject at risk for a cardiovascular disease or disorder by first identifying a suitable subject with prostate cancer and at risk for a cardiovascular disease or disorder.
  • the suitable subject with cardiovascular disease risk is then administered an initial dose of 160-320 mg of degarelix, followed by a maintenance dose of 60-160 mg of degarelix delivered once every approximately 28 days thereafter, thereby treating prostate cancer in the subject at risk for a cardiovascular disease or disorder with a reduced likelihood of causing a testosterone spike or other GnRH agonist side-effect.
  • the maintenance dose of degarelix is administered monthly.
  • the treated subject has a body mass index of less than 30 kg/m 2 (particularly a BMI of less than 25 kg/m 2 ).
  • the treated subject is at risk of a cardiovascular disease or disorder, such as a cardiac murmur, an atrioventricular blockage, and/or myocardial ischemia.
  • the treated subject possesses an indicator of increased risk for cardiovascular disease.
  • the treated subject possesses an indicator of increased risk for cardiovascular disease, e.g. high blood pressure, high low-density lipoprotein cholesterol, low high-density lipoprotein cholesterol, high serum glucose and/or a habitual smoking habit.
  • the treated subject has high blood pressure of greater than or equal to 130 over 85 mm Hg. In further embodiments, the treated subject smokes cigarettes daily. In still further embodiments, the treated subject has an elevated level of low-density lipoprotein cholesterol of greater than or equal to about 160 mg/dL. In further embodiments, the treated subject has a low level of high-density lipoprotein cholesterol of less than 35 mg/dl. In other embodiments, the treated subject has an elevated fasting glucose level of greater than about 120 mg/dL.
  • the treated subject possesses an indicator of increased risk for cardiovascular disease such as high serum C-reactive protein (CRP), high serum homocysteine, high serum fibrinogen, and/or high serum lipoprotein(a) (Lp(a)).
  • CRP C-reactive protein
  • Lp(a) high serum lipoprotein(a)
  • the treated subject has an elevated level of C-reactive protein of greater than 3 mg/dL.
  • the treated subject has an elevated level of serum homocysteine of greater than 30 ⁇ mol/L.
  • the treated subject has an elevated level of serum fibrinogen of greater than 7.0 g/L.
  • the treated subject has an elevated level of serum Lp(a) of greater than 30 mg/dL.
  • the treated subject has a decreased likelihood, when compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide, of developing a cardiovascular side effect such as a cardiac arrhythmia, a coronary artery disorder, and/or a cardiac disorder.
  • the treated subject has a body mass index of less than 30 kg/m 2 (particularly less than 25 kg/m 2 ).
  • the invention provides a method of treating prostate cancer in a preferred subject by identifying a subject with prostate cancer having a body mass index of less than about 25 kg/m 2 .
  • the preferred subject thus identified is administered a single initial dose of 160-320 mg of degarelix, followed by monthly doses of 60-160 mg of degarelix administered once every 20-36 days thereafter.
  • the treated subject has a decreased likelihood, when compared to treatment with the gonadotrophin releasing hormone (GnRH) agonist leuprolide, of developing a cardiovascular side effect such as a cardiac arrhythmia, a coronary artery disorder, and/or a cardiac disorder.
  • GnRH gonadotrophin releasing hormone
  • the initial dose of degarelix is about 240 mg, and the maintenance dose of degarelix is about 80 mg administered monthly.
  • the preferred subject has a cholesterol level of greater than or equal to 4 mmol/L (155 mg/dL).
  • the methods of treatment of the invention may be with, or associated with, a reduced incidence or likelihood of one or more of cardiovascular and/or vascular side effects (for example with reduced incidence and/or likelihood of one or more of myocardial infarction, chest pain, chest pain development, cardiac murmur, cardiac murmur development, myocardial ischemia, atrioventricular blockage, deep vein thrombosis (DVT), cardiac arrhythmia, coronary artery disorder, and/or cardiac disorder), musculoskeletal disorder (for example arthralgia and/or musculoskeletal stiffness), connective tissue disorder, urinary and/or renal system disorder.
  • cardiovascular and/or vascular side effects for example with reduced incidence and/or likelihood of one or more of myocardial infarction, chest pain, chest pain development, cardiac murmur, cardiac murmur development, myocardial ischemia, atrioventricular blockage, deep vein thrombosis (DVT), cardiac arrhythmia, coronary artery disorder, and/or cardiac disorder
  • FIG. 1 is a depiction of the chemical structure of degarelix.
  • FIG. 2 is a graphical representation of the effect of degarelix 240 mg/80 mg dosing on plasma testosterone from day 0 to day 364 of treatment.
  • FIG. 3 is a graphical representation comparing the effect of degarelix 240 mg/80 mg dosing with the effect of Lupron 7.5 mg dosing on the percentage change in plasma testosterone from day 0 to day 28 of treatment.
  • FIG. 4 is a graphical representation comparing the effect of degarelix 240 mg/160 mg and degarelix 240 mg/80 mg dosing with the effect of Lupron 7.5 mg dosing on the median levels of luteinizing hormone (LH) over time from day 0 to day 364 of treatment.
  • LH luteinizing hormone
  • FIG. 5 is a graphical representation comparing the effect of degarelix 240 mg/160 mg and degarelix 240 mg/80 mg dosing with the effect of Lupron 7.5 mg dosing on the median levels of follicle stimulating hormone (FSH) over time from day 0 to day 364 of treatment.
  • FSH follicle stimulating hormone
  • FIG. 6 is a graphical representation comparing the effect of degarelix 240 mg/80 mg dosing with the effect of Lupron 7.5 mg dosing on prostate specific antigen (PSA) levels from day 0 to day 56 of treatment.
  • PSA prostate specific antigen
  • the invention provides methods of treating prostate cancer with degarelix GnRH antagonist using a dosing regimen that results in optimal efficacy, and reduced serious side-effects, particularly in certain patient subgroups, compared to other androgen deprivation therapies, particularly GnRH agonist therapies such as leuprolide.
  • the relative efficacy and safety (including adverse side effects) of the GnRH agonist therapy leuprolide is known in the art (see e.g., Persad (2002) Int. J. Clin. Pract. 56:389-96; Wilson et al. (2007) Expert Opin. Invest. Drugs 16:1851-63; and Berges et al. (2006) Curr. Med. Res. Opin. 22:649-55).
  • the relative efficacy and safety of the GnRH antagonist therapy abarelix (PLENAXIS) has also been reported (see, e.g., Mongiat-Artus et al. (2004) Expert Opin. Pharmacother.
  • ADR refers to an adverse drug reaction
  • AE refers to an “adverse event.”
  • agonist as used herein, is meant to refer to an agent that mimics or up-regulates (e.g., potentiates or supplements) the bioactivity of a protein.
  • An agonist can be a wild-type protein or derivative thereof having at least one bioactivity of the wild-type protein.
  • Antagonist as used herein is meant to refer to an agent that down-regulates (e.g., suppresses or inhibits) at least one bioactivity of a protein.
  • arthralgia refers to pain in one or more joints, which may occur as a symptom of injury, infection, illnesses—in particular arthritis—or an allergic reaction to medication.
  • arthritis an allergic reaction to medication.
  • arthralgia specifically refers to non-inflammatory conditions, and the term “arthritis” should be used when the condition is an inflammatory condition.
  • body mass index refers to a statistical measure of the weight of a person scaled according to height, which is an approximating measure of the relative percentages of fat and muscle mass in the human body. BMI is defined as the individual's body weight divided by the square of their height, and the formulas used in medicine produce a unit of measure of kg/m 2 .
  • CI refers to a statistical confidence interval
  • cardiovascular refers to conditions involving the heart and/or blood vessels.
  • cardiac arrhythmia as used herein is any of a group of conditions in which the electrical activity of the heart is irregular or is faster or slower than normal.
  • coronary artery disorder or “coronary artery disease” refers to a condition (such as sclerosis or thrombosis) that reduces the blood flow through the coronary arteries to the heart muscle.
  • cardiac disorder refers to any of a number of abnormal organic conditions affecting the heart including coronary heart disease, heart attack, cardiovascular disease, pulmonary heart disease and high blood pressure.
  • Deep-vein thrombosis also known as deep-venous thrombosis or DVT
  • DVT deep-venous thrombosis
  • thrombus blood clot
  • leg veins such as the femoral vein or the popliteal vein or the deep veins of the pelvis.
  • Thrombophlebitis is the more general class of pathologies of this kind. There is a significant risk of the thrombus embolizing and traveling to the lungs causing a pulmonary embolism.
  • ECG refers to an electrocardiogram
  • MedDRA refers to the Medical dictionary for regulatory activities.
  • myocardial infarction refers to an infarction of the myocardium that results typically from coronary occlusion, which may be marked by sudden chest pain, shortness of breath, nausea, and loss of consciousness, and sometimes death.
  • An “infarction” refers to the process of forming an infarct, which is an area of necrosis in a tissue or organ resulting from obstruction of the local circulation by a thrombus or embolus.
  • “Male sexual dysfunction” includes impotence, loss of libido, and erectile dysfunction.
  • Esrectile dysfunction is a disorder involving the failure of a male mammal to achieve erection, ejaculation, or both.
  • prostate cancer refers to any cancer of the prostate gland in which cells of the prostate mutate and begin to multiply out of control.
  • the term “prostate cancer” includes early stage, localized, cancer of the prostate gland; later stage, locally advanced cancer of the prostate gland; and later stage metastatic cancer of the prostate gland (in which the cancer cells spread (metastasize) from the prostate to other parts of the body, especially the bones and lymph nodes).
  • PSA prostate-specific antigen
  • PD refers to pharmacodynamic
  • PK refers to pharmacokinetic
  • PT refers to a preferred term.
  • SAE refers to a serious adverse event
  • SD refers to standard deviation
  • SOC refers to a system organ class
  • SUSAR refers to a suspected, unexpected serious adverse reaction.
  • a “subject” or “patient” is a male mammal, more preferably a human male.
  • Non-human male mammals include, but are not limited to, farm animals, sport animals, and pets.
  • UTI urinary tract infection
  • Degarelix is a potent GnRH antagonist that is an analog of the GnRH decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH 2 ) incorporating p-ureido-phenylalanines at positions 5 and 6 (Jiang et al. (2001) J. Med. Chem. 44:453-67). It is indicated for treatment of patients with prostate cancer in whom androgen deprivation is warranted (including patients with rising PSA levels after having already undergone prostatectomy or radiotherapy).
  • Degarelix is a selective GnRH receptor antagonist (blocker) that competitively and reversibly binds to the pituitary GnRH receptors, thereby rapidly reducing the release of gonadotrophins and consequently testosterone (T).
  • Prostate cancer is sensitive to testosterone deprivation, a mainstay principle in the treatment of hormone-sensitive prostate cancer.
  • GnRH receptor blockers do not induce a luteinizing hormone (LH) surge with subsequent testosterone surge/tumor stimulation and potential symptomatic flare after the initiation of treatment.
  • Degarelix is available as a powder for injectable formulation and a solvent for reconstitution of the powder.
  • the powder for injectable formulation is a lyophilisates containing degarelix and mannitol, and the solvent consists of water for injection provided in 6 mL vials.
  • the active ingredient degarelix is a synthetic linear decapeptide amide containing seven unnatural amino acids, five of which are D-amino acids.
  • the drug substance is an acetate salt, but the active moiety of the substance is degarelix as the free base.
  • the acetate salt of degarelix is a white to off-white amorphous powder of low density as obtained after lyophilisation.
  • the chemical name is D-Alaninamide, N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L leucyl-N-6-(1-methylethyl)-L-lysyl-L-prolyl. It has an empirical formula of C 82 H 103 N 18 O 16 Cl and a molecular weight of 1,632.3 Da.
  • the chemical structure is of degarelix is shown in FIG. 1 and may also be represented by the formula:
  • Degarelix is one member of a family of GnRH antagonists, described in further detail in U.S. Pat. No. 5,925,730 and EP 1003774 that carry modifications in positions 5 and 6 and have potent GnRH receptor binding activity as well as the particularly advantageous property of long duration of bioactivity.
  • Related GnRH antagonists are known in the art and described, e.g., in U.S. Pat. No. 5,821,230 and U.S. Pat. No. 6,214,798.
  • a preferred dosing regimen for treating adult males with prostate cancer is a single 240 mg starting dose of degarelix administered as two subcutaneous injections of 120 mg; and followed by monthly maintenance doses of 80 mg of degarelix administered as a single subcutaneous injection beginning approximately one month after the initial starting dose.
  • Degarelix may be formulated for administration subcutaneously, as opposed to intravenously, generally in the abdominal region, as described in further detail below.
  • the injection site may vary periodically to adapt the treatment to injection site discomfort.
  • injections should be given in areas where the patient will not be exposed to pressure, e.g. not close to waistband or belt and not close to the ribs.
  • degarelix by subcutaneous or intramuscular injection works well, but daily injections are generally not acceptable and so a depot formulation of degarelix may be utilized as describe in further detail in WO 03/006049 and U.S. Pub. Nos. 20050245455 and 20040038903.
  • subcutaneous administration of degarelix may be conducted using a depot technology in which the peptide is released from a biodegradable polymer matrix over a period of (typically) one to three months.
  • Degarelix and related GnRH antagonist peptides as described in WO 03/006049 and U.S. Pub. Nos. 2005/0245455 and 2004/0038903, have a high affinity for the GnRH receptor and are much more soluble in water than other GnRH analogues.
  • Degarelix and these related GnRH antagonists are capable of forming a gel after subcutaneous injection, and this gel can act as a depot from which the peptide is released over a period of weeks or even months.
  • a key variable for formation of an effective degarelix depot is the concentration of the solution in combination with the amount of substance administered per se. The concentration of the must be within a functional range. If the formulation is too dilute then no depot is formed and the long duration of action is lost, regardless of the amount of drug substance given. If the formulation is too concentrated then gel formation will occur before the drug can be administered.
  • Effective depot-forming formulations of degarelix generally have a concentration of not less than 5 mg/mL degarelix, e.g. 5 to 40 mg/mL of degarelix.
  • the dosing regimen for degarelix may be administered as an initial, starting dose of 240 mg administered as 6 mL of about 40 mg/mL (e.g., 2 injections of about 3 mL (e.g., 3.2 mL)) degarelix formulation, followed by monthly maintenance doses of 80 mg administered as a single injection of 4 mL of about 20 mg/mL degarelix formulation.
  • monthly maintenance doses of 160 mg may be utilized, e.g. by administering 4 mL of about 40 mg/mL degarelix every month.
  • degarelix may be provided as a powder for reconstitution (with a solvent) as a solution for injection (e.g. subcutaneous injection, e.g. to form a depot as described above).
  • the powder may be provided as a lyophilisate containing degarelix (e.g. as acetate) and mannitol.
  • a suitable solvent is water (e.g., water for injection, or WFI).
  • degarelix may be provided in a vial containing 120 mg degarelix (acetate) for reconstitution with about 3 mL WFI (e.g., 3.2 mL) such that each mL of solution contains about 40 mg degarelix.
  • degarelix may be provided in a vial containing 80 mg degarelix (acetate). After reconstitution with about 4 mL WFI each mL solution contains about 20 mg degarelix.
  • the reconstituted formulation should be a clear liquid, free of undissolved matter.
  • Degarelix is effective in achieving and maintaining testosterone suppression well below medical castration level of 0.5 ng/mL. As described below in further detail, maintenance monthly dosing of 80 mg resulted in sustained testosterone suppression in 97% of patients for at least one year and median testosterone levels after one year of treatment were 0.087 ng/mL.
  • degarelix Following subcutaneous administration of 240 mg degarelix (6 mL at a concentration of about 40 mg/mL) to prostate cancer patients, degarelix is eliminated in a biphasic fashion, with a median terminal half-life of approximately 43 days.
  • the long half-life after subcutaneous administration is a consequence of a very slow release of degarelix from the depot formed at the injection site(s).
  • the pharmacokinetic behavior of the drug is strongly influenced by its concentration in the injection formulation.
  • the resulting distribution volume in healthy elderly men is approximately 1 L/kg.
  • Plasma protein binding is estimated to be approximately 90%.
  • Degarelix is subject to common peptidic degradation during the passage of the hepato-biliary system and is mainly excreted as peptide fragments in the feces. No significant metabolites were detected in plasma samples after subcutaneous administration. In vitro studies have shown that degarelix is not a substrate for the human CYP450 system. Therefore, clinically significant pharmacokinetic interactions with other drugs are unlikely to occur.
  • Degarelix has been found to be generally well tolerated in clinical trials. The most commonly observed adverse reactions during degarelix therapy were due to the expected physiological effects of testosterone suppression, mainly hot flushes and increased weight, and injection site related adverse events, mainly injection site pain and injection site erythema.
  • liver function There was no evidence of any clinically significant changes in liver function. Few elevations of the liver enzymes were seen, and these changes were generally mild and transient.
  • degarelix therapeutic dosing regimen for the treatment of prostate cancer include a diminished likelihood of occurrence and/or diminished severity of symptoms of adverse reactions, adverse events or side effects to other organs or tissues.
  • An extensive panel of potential adverse events related to drug therapies has been described.
  • An adverse reaction dictionary allows investigators to identify the same adverse reaction with the same term and to identify different adverse reactions with different terms.
  • a standard dictionary may be used, however specialized pharmaceutical dictionaries have been develop to define adverse reaction terms and their synonyms (see Gillum (1989) “The Merck regulatory dictionary: A pragmatically developed drug effects vocabulary” Drug Info. J. 23:217-220).
  • the World Health Organization (WHO) Adverse Reaction Terminology is also available for delimiting the meanings of drug-induced side effects (see, e.g., Saltzman (1985) “Adverse reaction terminology standardization” Drug Info. J. 19:35-41).
  • COSTART provides a basis for vocabulary control of adverse reaction reports that emanate from a variety of sources. COSTART is organized primarily by anatomy. It has a hierarchical arrangement of terms, from the broadest (body-system categories) to the narrowest (specific preferred terms or even special search categories).
  • the COSTART dictionary is used and maintained by the Center for Drugs and Biologics at the Food and Drug Administration (FDA) for marketed medicine surveillance and has been endorsed by many senior managers in the various reviewing sections.
  • FDA Food and Drug Administration
  • index A comprising three lists including a body-system search categories, and a special search categories (e.g., neoplasia).
  • the WHO terminology system of adverse reactions is relatively short. A code number is assigned to each of these terms. This provides the advantage that the same code is retained when the term is translated into different languages.
  • the WHO system uses a hierarchy of “preferred terms” to describe adverse reactions. Other commonly used terms are called “included terms,” which are listed with their preferred terms.
  • MedDRA Medical dictionary for regulatory activities is a particularly useful source for definitions of adverse events relating to drug trials.
  • MedDRA utilizes pragmatic, medically valid terminology with an emphasis on ease of use for data entry, retrieval, analysis, and display, as well as a suitable balance between sensitivity and specificity within the regulatory environment. It was developed by the International Conference on Harmonisation (ICH) and is owned by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) acting as trustee for the ICH steering committee, and is readily available commercially (see, e.g., the MedDRA website at www.meddramsso.com).
  • the MedDRA Maintenance and Support Services Organization (MSSO) holds a contract with the International Federation of Pharmaceutical Manufacturers Associations (IFPMA) to maintain and support the implementation of the terminology.
  • MedDRA terminology applies to all phases of drug development, excluding animal toxicology, and has been utilized in the examples that follow.
  • cardiovascular anomalies e.g., cardiac arrhythmias, coronary artery disorders and cardiac disorders
  • arthralgia e.g., a number of other adverse reactions
  • urinary tract infection unexpectedly occur at a lower frequency than prior art androgen depletion therapies such as the GnRH antagonist leuprolide.
  • the invention includes methods for treating individuals with prostate cancer who are at risk for developing a cardiovascular disease, as well as methods of treating otherwise normal prostate cancer patients with a decreased likelihood of developing a cardiovascular side effect.
  • This aspect of the invention is particularly significant, in light of recent findings suggesting the possibility of an increased risk of death from nonprostate cancer causes, particularly relating to adverse effects on cardiovascular health, in patients being treated with prior art androgen deprivation therapies (see Yannucci et al. (2006) J. Urol. 176:520-5).
  • cardiovascular risk factors include: high blood pressure (particularly greater than or equal to 130 over 85 mm Hg); high levels of low-density lipoprotein cholesterol (particularly greater than or equal to 160 mg/dL); low levels of high-density lipoprotein cholesterol (particularly less than 35 mg/dL); high levels of serum glucose (particularly levels of fasting glucose levels greater than about 120 mg/dL); high serum levels of C-reactive protein (CRP) (particularly levels greater than 3 mg/dL); high serum levels of homocysteine (particularly levels greater than 30 ⁇ mol/L); high serum levels of serum fibrinogen (particularly levels greater than 7.0 g/L); and high serum levels of lipoprotein(a) (Lp(a)) (particularly levels of greater than 30 mg/dL).
  • habit particularly greater than or equal to 130 over 85 mm Hg
  • high levels of low-density lipoprotein cholesterol particularly greater than or equal to 160 mg/dL
  • low levels of high-density lipoprotein cholesterol particularly less than 35 mg/dL
  • the study also investigated whether degarelix is safe and effective with respect to achieving and maintaining testosterone suppression to castrate levels, evaluated as the proportion of patients with testosterone suppression ⁇ 0.5 ng/mL during 12 months of treatment, and compared serum levels of testosterone and prostate-specific antigen (PSA) using a degarelix dosing regimen versus leuprolide 7.5 mg during the first 28 days of treatment.
  • the study further compared the safety and tolerability using a degarelix dosing regimen compared to treatment with leuprolide 7.5 mg, and, further, compared testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), and PSA response with a degarelix dosing regimen compared to leuprolide 7.5 mg.
  • the study further compared patient reported outcomes (quality of life factors and hot flushes) using a degarelix dosing regimen as compared to leuprolide 7.5 mg during treatment. Finally, the study evaluated the pharmacokinetics of the degarelix dosing regimens investigated.
  • IMP Investigational Medicinal Product
  • patients in two treatment groups received a degarelix starting dose of 240 mg at a concentration of 40 mg/mL (240@40) on Day 0 administered as two equivalent subcutaneous (s.c.) injections of 120 mg each. Thereafter, patients received 12 additional single s.c. degarelix doses of either 80 mg at a concentration of 20 mg/mL (80@20: degarelix 240/80 mg group) or 160 mg at a concentration of 40 mg/mL (160@40: degarelix 240/160 mg group) administered s.c. every 28 days.
  • patients received active treatment with leuprolide 7.5 mg on Day 0 and every 28 days administered as a single intramuscular (i.m.) injection.
  • bicalutamide could be given as clinical flare protection at the Investigator's discretion.
  • This group received an initial dose of 240 mg at a concentration of 40 mg/mL (240@40) on Day 0. This starting dose was administered as two equivalent subcutaneous (s.c.) injections of 120 mg each. The group then received 12 maintenance doses of 160 mg at a concentration of 40 mg/mL (160@40) as single s.c doses of degarelix every 28 days.
  • This group also received an initial dose of 240 mg at a concentration of 40 mg/mL (240@40) on Day 0. This starting dose was administered as two equivalent s.c. injections of 120 mg each. The group then received 12 maintenance doses of 80 mg at a concentration of 20 mg/mL (80@20) as single s.c doses of degarelix every 28 days.
  • This group received the reference therapy leuprolide 7.5 mg. This treatment was administered as a single intramuscular (i.m.) injection, once every 28 days starting at Day 0.
  • Degarelix 240 @ 40 (as 2 doses 160 @ 40 (as 12 single 240/160 mg on Day 0) doses, one every 28 days)
  • Degarelix 240 @ 40 (as 2 doses 80 @ 20 (as 12 single doses, 240/80 mg on Day 0) one every 28 days)
  • Leuprolide 7.5 mg administered at Day 0 and every 28 days via 7.5 mg single intramuscular injection. Bicalutamide was given at the Investigator's discretion.
  • GnRH agonists, GnRH antagonists, antiandrogens, or estrogens resulted in exclusion from the study.
  • neoadjuvant hormonal treatment was accepted for a maximum duration of 6 months provided that this treatment had been terminated for at least 6 months prior to the screening visit.
  • Concurrent treatment with a 5- ⁇ -reductase inhibitor also resulted in exclusion from the study.
  • Patients who were candidates for a curative therapy i.e. radical prostatectomy or radiotherapy
  • Patients in the reference therapy group received treatment with leuprolide 7.5 mg on Day 0 and every 28 days thereafter for 12 maintenance doses. Patients who completed the study received thirteen doses in total. Patients who completed the study and met appropriate criteria were offered a switch to degarelix treatment in a continuing study. These patients were randomized to degarelix treatment 240/80 mg or 240/160 mg. On Day 0 of the study, patients previously treated with leuprolide 7.5 mg in study CS21 received a 240 mg (40 mg/mL) degarelix starting dose followed by monthly maintenance doses of either 80 mg (20 mg/mL) or 160 mg (40 mg/mL).
  • the primary efficacy endpoint was the probability of testosterone levels remaining ⁇ 0.5 ng/mL from day 28 through day 364.
  • the secondary efficacy endpoints were: the proportion of patients with testosterone surge during the first 2 weeks of treatment; the proportion of patients with testosterone level ⁇ 0.5 ng/mL at day 3; the percentage change in PSA from baseline to day 28; the probability of testosterone ⁇ 0.5 ng/mL from day 56 through day 364; the levels of serum testosterone, LH, FSH and PSA over time through the study; the time to PSA failure, defined as two consecutive increases of 50%, and at least 5 ng/mL as compared to nadir; degarelix concentration over the first month and trough levels at day 308 and 336; the frequency and size of testosterone increases at day 255 and/or 259 compared to the testosterone level at day 252; the quality of life on days 0, 28, 84,168 and end of study visit; the frequency and intensity of hot flushes experienced (scored daily from study start until end of study visit.
  • AEs adverse events
  • ECGs electrocardiograms
  • An adverse event was defined as any untoward medical occurrence in a patient or clinical investigation subject administered an investigational medical product (IMP) and which did not necessarily have a causal relationship with the study treatment.
  • An AE was therefore any unfavorable or unintended sign (including an abnormal laboratory finding), symptom or disease temporally associated with the use of the product, whether or not related to the IMP.
  • This definition also included accidental injuries and reasons for changes in medication (drug and/or dose), any medical, nursing or pharmacy consultation, or admission to hospital or surgical operations. It also included AEs commonly observed and AEs anticipated based on the pharmacological effect of the IMP. Any clinically significant injection site reaction of a severity requiring active management (ie. change in dose, discontinuation of study drug, more frequent follow-up or treatment of the injection site) was also considered to be an AE and was to be reported on the AE log. This definition was the minimum requirement for reporting of an AE related to injection site reactions. There may have been situations where there was no active follow-up but the reaction was still considered to be an AE.
  • ADR adverse drug reaction
  • An unexpected AE was defined as an AE not identified in nature, severity, or frequency in the section “undesirable effects” in the sponsor's current investigator's summary or in the leuprolide 7.5 mg package insert.
  • AEs could be volunteered spontaneously by the patient, or in response to general questioning about their well-being by the investigator, or as a result of changes in systemic and local tolerability, laboratory parameters or physical examinations. All AEs were recorded. The nature of each event, time and date of onset, duration, intensity, seriousness criteria, an assessment of its cause and relationship to the study medication, the need for specific therapy and its outcome were described. The action taken because of an AE was classified according to medicinal product (no change, discontinued, other change [specified]). All medications used to treat the AE were recorded in the concomitant medication log.
  • Any AE assessed by the investigator as serious, severe and/or possibly or probably related to the investigational product was to be followed until it had resolved or until the medical condition of the patient was stable and all relevant follow-up information had been reported to Ferring Pharmaceuticals A/S.
  • any AE related to liver function test (LFT) was to be followed by the investigator. The outcome of an AE was classified as recovered, recovered with sequelae, not yet recovered or death.
  • AEs were graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE). In accordance with the CTCAE criteria, AEs were rated on a five-point scale corresponding to mild, moderate, severe, life-threatening or disabling and death. For those AEs not described in the CTCAE, a separate five-point rating scale was used for rating of the intensity of AEs as follows below:
  • Grade 1 AEs Mild—Minor; no specific medical intervention; asymptomatic laboratory findings only, radiographic findings only; marginal clinical relevance.
  • Grade 2 AEs Moderate—minimal intervention to local intervention, or non-invasive intervention.
  • Grade 3 Severe—significant symptoms, requiring hospitalization or invasive intervention; transfusion; elective interventional radiological procedure; therapeutic endoscopy or operation.
  • Grade 4 Life-threatening or disabling—complicated by acute, life-threatening metabolic or cardiovascular complications such as circulatory failure, haemorrhage, sepsis; life-threatening physiologic consequences; need for intensive care or emergent invasive procedure; emergent interventional radiological procedure, therapeutic endoscopy or operation.
  • Probable clear-cut temporal association with improvement on cessation of test drug or reduction in dose; reappears upon re-challenge; follows a known pattern of response to test drug.
  • SAEs Serious adverse events
  • Blood pressures and pulse were measured at Screening, before dosing at each dosing visit, and at the end of study visit. Diastolic and systolic blood pressure and pulse were measured after resting for five minutes in a sitting position. Patients were observed clinically for at least 1 hour after each administration of investigational medical product (IMP) to observe for any immediate onset hypersensitivity reaction. During the observation period, diastolic and systolic blood pressure and pulse were measured at 5, 10, 30 and 60 minutes after dosing.
  • IMP investigational medical product
  • a 12-lead electrocardiogram was performed by site personnel at screening, day 0, day 3, every 12 weeks (84 days) after day 0 and at the end of study visit. ECGs were performed before dosing, if a dosing visit was scheduled. The ECGs were acquired digitally and the measurements were performed as known in the art. The ECG measurements included heart beat, PR, QRS intervals, QT and QTc, T and U wave.
  • Each patient also underwent a physical examination at screening, day 0, every 12 weeks thereafter and at the end of study visit. Any clinically significant abnormal findings observed at screening were recorded. Any clinically significant abnormal findings observed thereafter were recorded as AEs.
  • Body weight was measured at screening and the end of study visit. Height (without shoes) was measured at screening.
  • Body mass index (BMI) is defined as the individual's body weight divided by the square of their height. The formulas universally used in medicine produce a unit of measure of kg/m2. Body mass index may be accurately calculated using any of the formulas below.
  • the intention-to-treat (ITT) analysis set included all randomized patients who received at least one dose of investigational medicinal product (IMP).
  • the per protocol (PP analysis set) comprised all the ITT analysis set without any major protocol violations
  • the safety population was identical to the ITT analysis set, and therefore all safety analyses were performed on the ITT analysis set.
  • the primary efficacy endpoint was analyzed for both the ITT and PP analysis sets, with the ITT analysis set considered primary.
  • the primary efficacy endpoint was analyzed using the Kaplan Meier method.
  • testosterone response rates with 95% confidence interval (CI) were calculated by log-log transformation of survivor function.
  • Differences between the degarelix treatment groups and leuprolide 7.5 mg were assessed using a 97.5% CI calculated by normal approximation using pooled standard error.
  • the FDA criterion was to determine whether the lower bound of the 95% confidence interval (CI) for the cumulative probability of testosterone ⁇ 0.5 ng/mL from Day 28 to Day 364 was no lower than 90%.
  • the EMEA criterion was to determine whether degarelix was non-inferior to leuprolide 7.5 mg with respect to the cumulative probability of testosterone ⁇ 0.5 ng/mL from Day 28 to Day 364.
  • the non-inferiority limit for the difference between treatments (degarelix versus leuprolide 7.5 mg) was ⁇ 10 percentage points.
  • the secondary endpoints; probability of testosterone ⁇ 0.5 ng/mL from Day 56 through Day 364, time to PSA failure and probability of sufficient testosterone response from Day 28 through Day 364 were analyzed by the Kaplan-Meier method.
  • the primary objective of this study was to demonstrate the effectiveness of degarelix in achieving and maintaining testosterone suppression to castrate levels, evaluated as the proportion of patients with testosterone suppression ⁇ 0.5 ng/mL during 12 months of treatment.
  • Kaplan-Meier estimates of the probabilities of testosterone ⁇ 0.5 ng/mL from day 28 to day 364 were 98.3%, 97.2% and 96.4% for the degarelix 240/160 mg, degarelix 240/80 mg and leuprolide 7.5 mg groups, respectively.
  • the lower bound of the 95% CI was above the pre-specified 90% threshold.
  • Treatment with degarelix was demonstrated to be non-inferior to leuprolide 7.5 mg therapy with respect to the probability of testosterone ⁇ 0.5 ng/mL from day 28 to day 364.
  • the robustness of the results for the primary efficacy endpoint was supported by an observed cases analysis, which produced similar estimates of the overall proportion of patients with testosterone ⁇ 0.5 ng/mL from day 28 to day 364 for the degarelix 240/160 mg, degarelix 240/80 mg and leuprolide 7.5 mg groups of 98.2%, 97.0% and 96.0%, respectively.
  • the findings of the primary analysis were further supported by a secondary efficacy analysis of the probability of testosterone ⁇ 0.5 ng/mL from day 56 to day 364.
  • the degarelix 240/80 mg dosing regimen also produced a more rapid and efficient reduction in PSA levels than did treatment with Lupron 7.5 mg.
  • a rapid reduction in PSA levels was observed for patients treated with degarelix.
  • PSA levels in the leuprolide 7.5 mg group reached a plateau during the first week of treatment before decreasing exponentially to suppressed levels.
  • the probability of a PSA observation from the pooled degarelix groups being less than one from the leuprolide 7.5 mg group was slightly higher on day 14 (0.82) than on day 28 (0.70).
  • the probability of completing the study without experiencing PSA failure was highest in the degarelix 240/80 group (91.2%) and slightly lower ( ⁇ 85.8%) for both the degarelix 240/160 mg and leuprolide 7.5 mg groups, although this difference was not statistically significant.
  • Anti-androgen therapy was given to 22 patients in the leuprolide 7.5 mg group at the start of treatment for flare protection.
  • PSA data for these patients showed a greater median percentage change from baseline at day 14 (61.7% reduction) and day 28 (89.1%) compared to those patients in the leuprolide 7.5 mg group who did not receive anti-androgen therapy where the percentage reduction was 15.3% and 61.7% at days 14 and 28, respectively.
  • the median percentage change in PSA levels in the leuprolide plus antiandrogen patients was similar to those patients treated with degarelix, thereby confirming that degarelix is more effective than conventional GnRH agonist therapy at suppressing PSA at the start of treatment.
  • Degarelix does not require additional concomitant medication as prophylaxis for flare, yet a starting dose of 240 mg has a similar effect on PSA levels as the combination of GnRH agonist plus anti-androgen.
  • the pharmacodynamic profile for degarelix was characteristic of a GnRH antagonist with serum levels of testosterone, LH and FSH suppressed rapidly.
  • serum levels of testosterone, LH and FSH increased rapidly within the first week of treatment before falling to suppress levels.
  • Safety parameters were evaluated for all patients included in the ITT analysis set, comprising all 610 randomized patients who received at least one dose of study medication. All safety tables include four columns: the three treatment groups described separately, and the pooled degarelix group.
  • Adverse events were regarded as ‘treatment-emergent’ if they occurred in the time interval from initial dosing to end-of-study. Adverse events were considered ‘pre-treatment’ if they occurred between screening and the initial injections of IMP. As described above, all AEs were classified according to MedDRA (version 10.0) system organ class (SOC), sorted alphabetically, and by preferred term (PT), in decreasing frequency of occurrence. Treatment-emergent AEs were expressed in terms of intensity (using NCI CTCAE) and relationship to study drug. An overall summary of treatment-emergent AEs is presented in Table 5.
  • the overall percentages of patients experiencing treatment-emergent AEs were comparable across all three treatment groups. 167 (83%) patients in the degarelix 240/160 mg group reported treatment-emergent AEs, compared with 163 (79%) patients in the degarelix 240/80 mg group, and 156 (78%) patients in the leuprolide 7.5 mg group. In total, there were reports of ADRs in 238 (58%) pooled degarelix patients, with 120 (59%) patients in the degarelix 240/160 mg group, 118 (57%) patients in the degarelix 240/80 mg group. For the leuprolide 7.5 mg group, 42% patients reported ADRs.
  • Table 6 shows a summary of the number of patients reporting treatment-emergent AEs, presented by SOC. All treatment-emergent AEs are presented by system organ class and Med-DRA preferred term.
  • Treatment-emergent AEs were reported for a comparable percentage of patients across all three treatment groups: 83%, 79% and 78% of patients in the degarelix 240/160 mg, degarelix 240/80 mg and leuprolide 7.5 mg groups, respectively. As shown in Table B above, there were no marked differences between the SOCs affected for the two degarelix treatment groups.
  • the predominant system-organ class affected for degarelix patients in both treatment groups was ‘General Disorders and Administration Site Conditions’, reported for 47% pooled degarelix patients, and 18% leuprolide 7.5 mg patients. The majority of these AEs were injection site pain, which occurred in 29% of pooled degarelix patients.
  • ‘vascular disorders’ were reported for 33% degarelix patients, and 30% leuprolide 7.5 mg patients, primarily hot flushes.
  • Other SOCs affected in ⁇ 15% patients were: ‘investigations’ in 27% degarelix patients and 31% leuprolide 7.5 mg patients, ‘infections and infestations’ in 20% and 24% patients, respectively, ‘musculoskeletal and connective tissue disorders’ in 17% and 26% patients, respectively, and ‘gastrointestinal disorders’ in 17% and 19% patients, respectively.
  • the most frequently reported treatment-emergent AEs for patients treated with degarelix were injections site reactions (particularly injection site pain and erythema).
  • the most frequently reported AE for both degarelix and leuprolide patients during the study were flushing events: overall, 52 (26%) patients in the degarelix 240/160 mg group reported hot flushes, compared to 53 (26%) patients in the degarelix 240/80 mg group, and 43 (21%) patients in the leuprolide 7.5 mg group.
  • SOC/preferred term data further support the finding discussed above for diminished musculoskeletal disorders, and renal and urinary disorders for degarelix as compared to leuprolide treatments. For example, 9% of leuprolide patients experienced urinary tract infections during the course of treatment as compared to only 3% of all degarelix-treated patients. Similarly, 9% of leuprolide patients experienced arthralgia (joint pain) during the course of treatment while only 4% of all degarelix-treated patients experienced arthralgia.
  • Treatment-emergent AEs were reported by 330 (81%) patients in the pooled degarelix treatment groups and by 156 (78%) patients in the leuprolide 7.5 mg group. The majority of AEs were of mild or moderate intensity.
  • MedDRA preferred terms, the highest incidences were injection site pain (2.9 per 100 injections) and injection site erythema (1.9 per 100 injections) for the pooled degarelix group. All other preferred terms had an incidence rate of 0.5 per 100 injections or less. None of the injection-related ADRs were considered to be serious, and there were no immediate onset hypersensitivity reactions. Five (1.2%) patients reported degarelix-related injection site reactions, which led to withdrawal. Other commonly reported ADRs were hot flushes which were an expected adverse reaction associated with testosterone suppression. In total, hot flushes were reported by 104 (25%) patients treated with degarelix and 42 (21%) treated with leuprolide 7.5 mg. One patient treated with degarelix reported a hot flush ADR, which led to withdrawal. Notably, although AEs related to sexual dysfunction would be anticipated to result from testosterone suppression, very few were actually reported.
  • Weight increase is a known effect of androgen deprivation and markedly abnormal increases in weight of ⁇ 7% from baseline were observed in 10% patients treated with degarelix and 13% patients treated with leuprolide 7.5 mg. The incidence of other markedly abnormal changes in vital signs was consistent with a group of elderly patients many of whom had a medical history of cardiac disease or hypertension.
  • Abarelix/Plenaxis has been associated with serious allergic reactions (e.g., swelling of the tongue/throat, asthma, wheezing and serious breathing problems), and therefore is only available through a special “user safety program” to ensure that it is safely used by doctors with the right skills to administer and monitor the drug.
  • Subgroup distinguishers included race (white, black, and other), age ( ⁇ 65 years, ⁇ 65 years to ⁇ 70 years, and ⁇ 75 years), weight ( ⁇ 70 kg, ⁇ 70- ⁇ 90 kg, and ⁇ 90 kg), body mass index (BMI) ( ⁇ 20, >20 to 30, and >30 kg/m 2 )), region (North-America, Western Europe, Central and Eastern Europe and Other), and stage of prostate cancer (e.g., localized, locally advanced, and metastatic).
  • SCE clinical efficacy
  • SCS summary of clinical safety
  • the SCS summarizes both crude incidences (n/N) as well as incidence rates of adverse events (number of patients with at least one adverse event investigated per 1,000 person years) including exact 95% CI based on the Poisson model and presented per MedDRA Preferred term (and grouped by SOC) for all study-groups, including the CS21 trial (the trial comprising the controlled phase 3 study group) and for all sub-groups.
  • HLGT Central nervous system vascular disorders
  • HLGT Cardiac arrhythmias
  • HLGT Coronary artery disorders
  • Time to testosterone escape during Days 28, 56, . . . , 364 in the age ⁇ 65 subgroup is significantly superior to LUPRON DEPOT® 7.5 mg for both degarelix dosing regimens (see Table 8 below).
  • PSA percent change from baseline is more pronounced in the patients with metastatic stage prostate cancer (See Table 10 below). All subgroups are statistically significantly better than LUPRON DEPOT® 7.5 mg.
  • PT Myocardial Infarction
  • Chest pain 0.5% (2/409, degarelix combined) versus 3% (6/201, LUPRON DEPOT® 7.5 mg),
  • Urinary Tract infection 3% (13/409, degarelix combined) versus 9% (18/201, LUPRON DEPOT® 7.5 mg),
  • Musculoskeletal and connective tissue disorders SOC: 17% (68/409, degarelix combined) versus 26% (53/201, LUPRON DEPOT® 7.5 mg),
  • Musculoskeletal stiffness (PT within Musculoskeletal and CTD SOC): 0% (0/409, degarelix combined) versus 1% (3/201, LUPRON DEPOT® 7.5 mg),
  • Libido decreased: 0% (0/409, degarelix combined) versus 1.5% (3/201, LUPRON DEPOT® 7.5 mg),
  • Cystitis noninfective 0% (0/409, degarelix combined) versus 2% (4/201, LUPRON DEPOT® 7.5 mg),
  • Erectile dysfunction 1.5% (6/409, degarelix combined) versus 4.5% (9/201, LUPRON DEPOT® 7.5 mg),

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
US12/368,935 2008-02-11 2009-02-10 METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST Abandoned US20090203623A1 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US12/368,935 US20090203623A1 (en) 2008-02-11 2009-02-10 METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
US13/458,330 US9415085B2 (en) 2008-02-11 2012-04-27 Method of treating prostate cancer with GnRH antagonist
US14/139,922 US9579359B2 (en) 2008-02-11 2013-12-24 Method of treating prostate cancer with GnRH antagonist
US15/405,552 US10729739B2 (en) 2008-02-11 2017-01-13 Methods of treating prostate cancer with GnRH antagonist
US16/851,179 US10973870B2 (en) 2008-02-11 2020-04-17 Methods of treating prostate cancer with GnRH antagonist
US17/199,733 US20220031801A1 (en) 2008-02-11 2021-03-12 METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
US17/710,889 US20220218782A1 (en) 2008-02-11 2022-03-31 METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
EPEP08250703.9 2008-02-29
EP08250703 2008-02-29
US12/368,935 US20090203623A1 (en) 2008-02-11 2009-02-10 METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US13/458,330 Continuation-In-Part US9415085B2 (en) 2008-02-11 2012-04-27 Method of treating prostate cancer with GnRH antagonist
US14/139,922 Continuation US9579359B2 (en) 2008-02-11 2013-12-24 Method of treating prostate cancer with GnRH antagonist

Publications (1)

Publication Number Publication Date
US20090203623A1 true US20090203623A1 (en) 2009-08-13

Family

ID=39718285

Family Applications (15)

Application Number Title Priority Date Filing Date
US12/368,935 Abandoned US20090203623A1 (en) 2008-02-11 2009-02-10 METHOD OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
US12/368,713 Active 2029-07-09 US8841081B2 (en) 2008-02-11 2009-02-10 Method of treating metastatic stage prostate cancer
US13/458,330 Active US9415085B2 (en) 2008-02-11 2012-04-27 Method of treating prostate cancer with GnRH antagonist
US14/139,922 Active US9579359B2 (en) 2008-02-11 2013-12-24 Method of treating prostate cancer with GnRH antagonist
US14/454,825 Active US9877999B2 (en) 2008-02-11 2014-08-08 Methods for treating metastatic stage prostate cancer
US15/205,108 Active 2032-06-17 US10695398B2 (en) 2008-02-29 2016-07-08 Method of treating prostate cancer with GnRH antagonist
US15/405,552 Active US10729739B2 (en) 2008-02-11 2017-01-13 Methods of treating prostate cancer with GnRH antagonist
US15/845,391 Abandoned US20190167755A1 (en) 2008-02-11 2017-12-18 Methods for treating metastatic stage prostate cancer
US16/851,179 Active 2029-02-22 US10973870B2 (en) 2008-02-11 2020-04-17 Methods of treating prostate cancer with GnRH antagonist
US16/880,608 Active 2033-05-12 US11766468B2 (en) 2008-02-29 2020-05-21 Method of treating prostate cancer with GnRH antagonist
US17/199,733 Pending US20220031801A1 (en) 2008-02-11 2021-03-12 METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
US17/710,889 Abandoned US20220218782A1 (en) 2008-02-11 2022-03-31 METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
US17/710,905 Abandoned US20220218783A1 (en) 2008-02-11 2022-03-31 Methods for treating metastatic stage prostate cancer
US17/710,899 Active US11826397B2 (en) 2008-02-29 2022-03-31 Method of treating prostate cancer with GnRH antagonist
US17/829,134 Abandoned US20220323538A1 (en) 2008-02-11 2022-05-31 Methods for treating metastatic stage prostate cancer

Family Applications After (14)

Application Number Title Priority Date Filing Date
US12/368,713 Active 2029-07-09 US8841081B2 (en) 2008-02-11 2009-02-10 Method of treating metastatic stage prostate cancer
US13/458,330 Active US9415085B2 (en) 2008-02-11 2012-04-27 Method of treating prostate cancer with GnRH antagonist
US14/139,922 Active US9579359B2 (en) 2008-02-11 2013-12-24 Method of treating prostate cancer with GnRH antagonist
US14/454,825 Active US9877999B2 (en) 2008-02-11 2014-08-08 Methods for treating metastatic stage prostate cancer
US15/205,108 Active 2032-06-17 US10695398B2 (en) 2008-02-29 2016-07-08 Method of treating prostate cancer with GnRH antagonist
US15/405,552 Active US10729739B2 (en) 2008-02-11 2017-01-13 Methods of treating prostate cancer with GnRH antagonist
US15/845,391 Abandoned US20190167755A1 (en) 2008-02-11 2017-12-18 Methods for treating metastatic stage prostate cancer
US16/851,179 Active 2029-02-22 US10973870B2 (en) 2008-02-11 2020-04-17 Methods of treating prostate cancer with GnRH antagonist
US16/880,608 Active 2033-05-12 US11766468B2 (en) 2008-02-29 2020-05-21 Method of treating prostate cancer with GnRH antagonist
US17/199,733 Pending US20220031801A1 (en) 2008-02-11 2021-03-12 METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
US17/710,889 Abandoned US20220218782A1 (en) 2008-02-11 2022-03-31 METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
US17/710,905 Abandoned US20220218783A1 (en) 2008-02-11 2022-03-31 Methods for treating metastatic stage prostate cancer
US17/710,899 Active US11826397B2 (en) 2008-02-29 2022-03-31 Method of treating prostate cancer with GnRH antagonist
US17/829,134 Abandoned US20220323538A1 (en) 2008-02-11 2022-05-31 Methods for treating metastatic stage prostate cancer

Country Status (25)

Country Link
US (15) US20090203623A1 (ar)
EP (7) EP3360565A1 (ar)
JP (10) JP5876652B2 (ar)
KR (7) KR20220009504A (ar)
CN (4) CN103990107A (ar)
AU (2) AU2009213751B2 (ar)
BR (2) BRPI0908127A2 (ar)
CA (3) CA3235099A1 (ar)
CY (3) CY1115561T1 (ar)
DK (3) DK2505204T3 (ar)
EA (4) EA026521B1 (ar)
ES (3) ES2540235T3 (ar)
HK (4) HK1176552A1 (ar)
HR (3) HRP20140665T1 (ar)
IL (3) IL207295A (ar)
JO (1) JOP20090061B1 (ar)
MX (2) MX2010008817A (ar)
NZ (4) NZ587057A (ar)
PL (3) PL2650012T3 (ar)
PT (3) PT2650012E (ar)
RU (2) RU2504393C2 (ar)
SI (3) SI2249859T1 (ar)
TW (2) TWI442932B (ar)
WO (2) WO2009101530A1 (ar)
ZA (1) ZA201005697B (ar)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018085A1 (en) * 2001-07-12 2009-01-15 Ferring B.V. Use of a GnRH antagonist peptide in the treatment of sex hormone-dependent diseases
USRE49353E1 (en) 2012-09-26 2023-01-03 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
US11766468B2 (en) 2008-02-29 2023-09-26 Ferring B.V. Method of treating prostate cancer with GnRH antagonist

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
CN105663059A (zh) * 2009-05-01 2016-06-15 辉凌公司 用于治疗前列腺癌的组合物
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
RS55457B1 (sr) 2010-10-27 2017-04-28 Ferring Bv Postupak za proizvodnju degareliksa i njegovih intermedijara
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN104169425A (zh) 2011-03-09 2014-11-26 理查德·G·佩斯泰尔 前列腺癌细胞系、遗传标志及其用途
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
CA2873743C (en) 2012-05-14 2022-12-06 Prostagene, Llc Using modulators of ccr5 for treating cancer
RU2657444C2 (ru) 2012-06-01 2018-06-13 Ферринг Б.В. Получение дегареликса
EP2968566A1 (en) 2013-03-15 2016-01-20 AbbVie Inc. Compositions for use in treating heavy menstrual bleeding and uterine fibroids
WO2014186608A1 (en) * 2013-05-15 2014-11-20 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
WO2016030334A2 (en) * 2014-08-26 2016-03-03 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
WO2016183176A1 (en) * 2015-05-12 2016-11-17 Drexel University Compounds and compositions useful for treating or preventing cancer metastasis, and methods using same
BR112019014192A2 (pt) * 2017-01-30 2020-02-11 Antev Limited Composição compreendendo pelo menos um antagonista de gnrh
WO2019203870A1 (en) 2018-04-19 2019-10-24 Abbvie Inc. Methods of treating heavy menstrual bleeding
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
CA3107597A1 (en) * 2018-08-01 2020-02-06 Abbvie Inc. Dosing regimens for elagolix
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494A (zh) * 2023-03-02 2023-07-11 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5516887A (en) * 1991-04-25 1996-05-14 Romano Deghenghi Luteinizing hormone releasing hormone antagonist peptides
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5863549A (en) * 1992-10-14 1999-01-26 Hoffmann-La Roche Inc. Methods for the sustained release of biologically active compounds
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US6503534B1 (en) * 1998-03-25 2003-01-07 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Pharmaceutical compositions for prolonged peptide release and preparation method
US20040038903A1 (en) * 2001-07-12 2004-02-26 Martin Luck Gonadotropin releasing hormone antagonists in gel-forming concentration
US20040138610A1 (en) * 2002-12-26 2004-07-15 Michel Cormier Active agent delivery device having composite members
US20080032935A1 (en) * 2006-08-07 2008-02-07 Aeterna Zentaris Gmbh Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
US20090209939A1 (en) * 2008-02-11 2009-08-20 Verespej James M Reconstitution means for safety device
US9415085B2 (en) * 2008-02-11 2016-08-16 Ferring B.V. Method of treating prostate cancer with GnRH antagonist

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE69330107T3 (de) 1992-02-12 2004-12-30 Daikyo Gomu Seiko, Ltd. Medizinisches Gerät
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
JP3688381B2 (ja) 1995-03-10 2005-08-24 株式会社東芝 光ディスク原盤露光装置
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5977302A (en) 1997-11-20 1999-11-02 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of GnRH peptides
BR9912275A (pt) 1998-07-20 2001-04-17 Peptech Ltd Formulação de bioimplante
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
IL158969A0 (en) * 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
RS52966B (en) 2002-09-27 2014-02-28 Zentaris Gmbh FORM OF THE THERAPEUTIC APPLICATION OF ACTIVE PEPTIDES WITH THE LONG TERM RELEASE OF THE ACTIVE INGREDIENT
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
EP1674082A1 (de) 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
JP6078217B2 (ja) 2008-01-15 2017-02-08 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 粉末化されたタンパク質組成物及びその作製方法
DK2421887T3 (en) 2009-04-24 2015-07-27 Polypeptide Laboratories As A process for the preparation of degarelix
CN105663059A (zh) 2009-05-01 2016-06-15 辉凌公司 用于治疗前列腺癌的组合物
TW201043221A (en) 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
RS55457B1 (sr) 2010-10-27 2017-04-28 Ferring Bv Postupak za proizvodnju degareliksa i njegovih intermedijara
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
CA2841751A1 (en) 2011-07-15 2013-01-24 Raymond E. Joseph Method for timing a colonoscopy wherein a picosulate composition is administered
RU2657444C2 (ru) 2012-06-01 2018-06-13 Ферринг Б.В. Получение дегареликса

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US5516887A (en) * 1991-04-25 1996-05-14 Romano Deghenghi Luteinizing hormone releasing hormone antagonist peptides
US5863549A (en) * 1992-10-14 1999-01-26 Hoffmann-La Roche Inc. Methods for the sustained release of biologically active compounds
US5506207A (en) * 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
US5925730A (en) * 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US6214798B1 (en) * 1997-04-11 2001-04-10 Ferring Bv GnRH antagonists being modified in positions 5 and 6
US6503534B1 (en) * 1998-03-25 2003-01-07 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Pharmaceutical compositions for prolonged peptide release and preparation method
US20040038903A1 (en) * 2001-07-12 2004-02-26 Martin Luck Gonadotropin releasing hormone antagonists in gel-forming concentration
US20050245455A1 (en) * 2001-07-12 2005-11-03 Martin Luck Gonadotropin releasing hormone antagonists in gel-forming concentrations
US20090018085A1 (en) * 2001-07-12 2009-01-15 Ferring B.V. Use of a GnRH antagonist peptide in the treatment of sex hormone-dependent diseases
US20040138610A1 (en) * 2002-12-26 2004-07-15 Michel Cormier Active agent delivery device having composite members
US20080032935A1 (en) * 2006-08-07 2008-02-07 Aeterna Zentaris Gmbh Application of initial doses of lhrh analogues and maintenance doses of lhrh antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
US20090209939A1 (en) * 2008-02-11 2009-08-20 Verespej James M Reconstitution means for safety device
US9415085B2 (en) * 2008-02-11 2016-08-16 Ferring B.V. Method of treating prostate cancer with GnRH antagonist
US9579359B2 (en) * 2008-02-11 2017-02-28 Ferring B.V. Method of treating prostate cancer with GnRH antagonist

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090018085A1 (en) * 2001-07-12 2009-01-15 Ferring B.V. Use of a GnRH antagonist peptide in the treatment of sex hormone-dependent diseases
US20110053846A1 (en) * 2001-07-12 2011-03-03 Ferring B.V. The use of gnrh antagonist peptide in the treatement of sex hormone-dependent diseases
US11766468B2 (en) 2008-02-29 2023-09-26 Ferring B.V. Method of treating prostate cancer with GnRH antagonist
US11826397B2 (en) 2008-02-29 2023-11-28 Ferring B.V. Method of treating prostate cancer with GnRH antagonist
USRE49353E1 (en) 2012-09-26 2023-01-03 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer

Also Published As

Publication number Publication date
CN107412726A (zh) 2017-12-01
US20140113870A1 (en) 2014-04-24
ES2540235T3 (es) 2015-07-09
IL207400A (en) 2014-12-31
CY1116341T1 (el) 2017-02-08
JP2016216455A (ja) 2016-12-22
EA200901075A1 (ru) 2010-04-30
US20220218783A1 (en) 2022-07-14
US9579359B2 (en) 2017-02-28
US20200237854A1 (en) 2020-07-30
US20210128673A1 (en) 2021-05-06
PL2650012T3 (pl) 2015-08-31
JOP20090061B1 (ar) 2021-08-17
EP2249858A1 (en) 2010-11-17
JP2016193910A (ja) 2016-11-17
EP2505204A2 (en) 2012-10-03
CY1116289T1 (el) 2017-02-08
CA3235099A1 (en) 2009-08-20
US20220031801A1 (en) 2022-02-03
NZ603932A (en) 2014-04-30
AU2009213751B2 (en) 2014-09-25
US20090203622A1 (en) 2009-08-13
RU2504394C2 (ru) 2014-01-20
US20220323538A1 (en) 2022-10-13
EP2799085A1 (en) 2014-11-05
EP2650012B1 (en) 2015-03-25
KR20150091543A (ko) 2015-08-11
BRPI0908127A2 (pt) 2015-08-04
US10973870B2 (en) 2021-04-13
HRP20140665T1 (hr) 2014-10-10
KR20220009504A (ko) 2022-01-24
JP2022184898A (ja) 2022-12-13
US20170290879A1 (en) 2017-10-12
JP6618967B2 (ja) 2019-12-11
TWI539959B (zh) 2016-07-01
JP2014167009A (ja) 2014-09-11
HK1198243A1 (en) 2015-03-20
CN103990107A (zh) 2014-08-20
PT2249859E (pt) 2014-07-31
DK2650012T3 (da) 2015-06-15
JP2022133426A (ja) 2022-09-13
PT2505204E (pt) 2015-03-26
IL223124A0 (en) 2012-12-31
US20140349935A1 (en) 2014-11-27
JP2024028869A (ja) 2024-03-05
CA2714444A1 (en) 2009-08-20
WO2009101533A1 (en) 2009-08-20
US20220218782A1 (en) 2022-07-14
IL207295A0 (en) 2010-12-30
PT2650012E (pt) 2015-06-30
JP5876652B2 (ja) 2016-03-02
US20190167755A1 (en) 2019-06-06
US20170035833A1 (en) 2017-02-09
JP2014141505A (ja) 2014-08-07
NZ603958A (en) 2013-03-28
MX2010008817A (es) 2010-09-09
JP6254042B2 (ja) 2017-12-27
CN101939020A (zh) 2011-01-05
SI2249859T1 (sl) 2014-08-29
US10729739B2 (en) 2020-08-04
US9415085B2 (en) 2016-08-16
KR20140130757A (ko) 2014-11-11
CA2714445A1 (en) 2009-08-20
KR20100123714A (ko) 2010-11-24
BRPI0908129A2 (pt) 2015-08-04
JP2011511785A (ja) 2011-04-14
EA020543B1 (ru) 2014-12-30
EA201300741A1 (ru) 2014-02-28
EP2505204A3 (en) 2013-01-09
CY1115561T1 (el) 2017-01-04
KR20230088848A (ko) 2023-06-20
DK2505204T3 (da) 2015-03-16
EP3360565A1 (en) 2018-08-15
RU2504393C2 (ru) 2014-01-20
SI2650012T1 (sl) 2015-06-30
TWI442932B (zh) 2014-07-01
CN101939020B (zh) 2012-12-26
EA201300742A1 (ru) 2014-02-28
US11826397B2 (en) 2023-11-28
HRP20150633T1 (hr) 2015-07-31
JP7400029B2 (ja) 2023-12-18
NZ587057A (en) 2012-12-21
AU2009213748A1 (en) 2009-08-20
AU2009213751A1 (en) 2009-08-20
ZA201005697B (en) 2014-01-24
US8841081B2 (en) 2014-09-23
EP4257197A2 (en) 2023-10-11
HK1190912A1 (en) 2014-07-18
IL207400A0 (en) 2010-12-30
JP2011511786A (ja) 2011-04-14
US10695398B2 (en) 2020-06-30
CN101998861A (zh) 2011-03-30
EP2249859A1 (en) 2010-11-17
ES2532709T3 (es) 2015-03-31
EP2249859B1 (en) 2014-04-23
JP6189234B2 (ja) 2017-08-30
US20220226422A1 (en) 2022-07-21
EA200901074A1 (ru) 2010-04-30
WO2009101530A1 (en) 2009-08-20
KR101542480B1 (ko) 2015-08-07
MX2010008816A (es) 2010-09-07
US9877999B2 (en) 2018-01-30
CA2714445C (en) 2018-01-16
RU2010133481A (ru) 2012-03-20
HK1145011A1 (en) 2011-03-25
EP4257197A3 (en) 2023-11-29
DK2249859T3 (da) 2014-06-02
TW200938217A (en) 2009-09-16
US11766468B2 (en) 2023-09-26
TW200938218A (en) 2009-09-16
KR20100126362A (ko) 2010-12-01
EA036695B1 (ru) 2020-12-09
EP2505204B1 (en) 2014-12-24
IL207295A (en) 2015-03-31
PL2249859T3 (pl) 2014-10-31
NZ587088A (en) 2012-12-21
PL2505204T3 (pl) 2015-05-29
US20130029910A1 (en) 2013-01-31
AU2009213748B9 (en) 2014-05-22
JP5924866B2 (ja) 2016-05-25
ES2479441T3 (es) 2014-07-24
EA026521B1 (ru) 2017-04-28
JP2018039814A (ja) 2018-03-15
EP2650012A1 (en) 2013-10-16
HK1176552A1 (en) 2013-08-02
SI2505204T1 (sl) 2015-04-30
KR20180118830A (ko) 2018-10-31
RU2010133480A (ru) 2012-03-20
EA017582B1 (ru) 2013-01-30
HRP20150290T1 (hr) 2015-04-10
AU2009213748B2 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
US10973870B2 (en) Methods of treating prostate cancer with GnRH antagonist
AU2014203174B2 (en) Method of treating prostate cancer with the gnrh antagonist degarelix
JP7104003B2 (ja) Ｇｎｒｈアンタゴニストであるデガレリクスを用いる前立腺癌の治療方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: FERRING B.V., NETHERLANDS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:OLESEN, TINE KOLD;PERSSON, BO-ERIC;CANTOR, PER;AND OTHERS;SIGNING DATES FROM 20140307 TO 20141215;REEL/FRAME:035792/0507

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION